Sunitinib Malate Market

The sunitinib malate market size for pancreatic cancer is projected to grow at a CAGR of 13.9%. Over the years, the sunitinib malate market for pancreatic cancer has observed steady growth and this trend is expected to continue in the coming years. This is primarily because the market is witnessing increasing adoption of drug therapy for the treatment of pancreatic cancer. This report categorizes patients with pancreatic neuroendocrine tumors (pNET) based on three different stages, namely, localized, advanced, and distant. The number of patients suffering from distant pNET is higher as this type of tumor causes practically no symptoms, owing to which it is difficult to diagnose it in early stages.

The U.S. is the largest market for sunitinib malate for the treatment of pancreatic cancer, followed by Japan and Germany. Growth in the U.S. market is primarily driven by the higher incidence of pancreatic cancer and the growing adoption of sunitinib malate for pNET treatment.

A number of factors, such as the growing number of pancreatic cancer patients, poor diagnosis rates in early stages of pancreatic cancer, and availability of a limited number of drug therapy options for the treatment of advanced pNET are driving the demand of sunitinib malate in the treatment of pancreatic cancer. Also, the overall number of patients who are eligible for taking sunitinib malate is expected to increase at a CAGR of more than 4% in G7 countries during the forecast period.

The market sizing and forecasting of sunitinib malate for pancreatic cancer was done in four steps. In the first step, the number of patient and their growth rate was identified based on epidemiology studies. The incidence and five-year survival of patients suffering from pNET cancer was considered. In the second step, treatment options were identified based on stage and type of tumor. Through this, the number of patients eligible for sunitinib malate was estimated. In the third step, the annual cost of therapy was estimated based on dosage regimen and price of products. In the final step, the market size of sunitinib malate for pancreatic cancer was estimated based on the number of patients eligible for sunitinib malate, annual cost of therapy, and inflation rate.

Target Audience

• Pharmaceutical Companies
• CROs
• Hospitals
• Oncology Centers
• Health Insurance Payers
• Regulatory Authorities
• Medical Oncologists
• Oncology Registries

To know about the assumptions considered for the study, download the pdf brochure

Sunitinib Malate Market Report Scope

This report provides quantitative assessment of the sunitinib malate market for pancreatic cancer in terms of epidemiology (incidence, 5-year survival rate), number of drug-treated patients suffering from pancreatic neuroendocrine tumor, percentage of patients eligible for taking sunitinib malate, penetration of sunitinib malate in pNET patients, pricing analysis of sunitinib malate in all G7 countries, and year-on-year market size of sunitinib malate for pancreatic cancer from 2010 to 2021.

Disease Overview

Clinical Staging

Product Profile

Sutent Market for Pancreatic Cancer

• U.S.
• Japan
• Germany
• France
• U.K.
• Italy
• Spain

This report provides quantitative assessment of the sunitinib malate market for pancreatic cancer in terms of epidemiology, number of drug-treated patients suffering from pancreatic neuroendocrine tumors (pNET), percentage of patients eligible for taking sunitinib malate, and year-on-year market size of sunitinib malate for pancreatic cancer from 2010 to 2021.

The overall sunitinib malate market for pancreatic cancer is expected to witness rapid growth owing to the increasing number of patients suffering from pancreatic cancer and growing adoption of sunitinib malate drug for pNET treatment. This report has divided the market in seven country-level segments, namely, U.S., Germany, France, U.K., Italy, Spain, and Japan. The U.S. is expected to be the largest market for sunitinib malate for pancreatic cancer, primarily due to the higher number of patients suffering from pancreatic cancer in the country. However, the market in the U.K. is expected to witness the highest growth rate during the forecast period.

This study provides an analytical framework to understand various factors that influence the growth of the sunitinib malate market for pancreatic cancer. These factors include incidence rate of pancreatic cancer, five-year survival rate of pNET patients, penetration of drug therapy for pancreatic cancer treatment, penetration of sunitinib malate in pNET patients, and trends in the adoption of sunitinib malate, among other factors. The importance of these parameters differs from country to country.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst